All over healthcare the big fish, little fish story is either taking place or actions are in the making for offers. There certainly are a number of big Pharma companies with money to foot the bill, that is if the Biotech companies see it fit to consider the options.
One problem as indicated in this article is the way business is conducted in Biotech versus how it is conducted in Pharma, a bit of a difference, especially with all the news of late. Biotech has had more of a consumer generated business model, where as Pharma has been big multi marketing campaigns. There's a bit of a difference between the 2 mildly stated. So can the two cultures live together is the question without hurting research and development efforts? The Biotech folks for the most part certainly seem to be in the driver's seat, as having what big Pharma wants, just a matter of price and culture. BD
But an independent company Gilead's size might be harder to acquire than Chiron or Genentech, Milligan said. If an outsider made a bid to buy all its shares, Gilead's board would probably seek rival offers and set off an expensive bidding war. "The shareholders, of course, would demand a premium," he said. "It would be a hefty premium, I would imagine."
The same argument could be made with regard to Amgen Inc. of Thousand Oaks (Ventura County), an independent company that leads the biotech industry in sales, and whose market cap is nearly $68 billion.
McCamant, however, points to Pfizer's history of acquiring other very large pharmaceutical companies as it became the world's largest drugmaker. Giant drug firms may not be daunted by a big biotech price tag, he said.
0 comments :
Post a Comment